---
title: "LRMR.US (LRMR.US) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/LRMR.US/news.md"
symbol: "LRMR.US"
name: "LRMR.US"
parent: "https://longbridge.com/en/quote/LRMR.US.md"
datetime: "2026-05-21T14:47:32.184Z"
locales:
  - [en](https://longbridge.com/en/quote/LRMR.US/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/LRMR.US/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/LRMR.US/news.md)
---

# LRMR.US (LRMR.US) — Related News

### [Larimar Shareholders Approve Governance and Capital Structure Changes](https://longbridge.com/en/news/286968564.md)
*2026-05-19T21:14:37.000Z*
> Larimar Therapeutics shareholders approved governance and capital structure changes during the 2026 Annual Meeting, incl

### [](https://longbridge.com/en/news/286454983.md)
*2026-05-14T17:36:16.000Z*
> Larimar Therapeutics shares are trading lower. The company reported Q1 EPS results.

### [Larimar Therapeutics | 8-K: FY2026 Q1 Revenue: USD 0](https://longbridge.com/en/news/286404170.md)
*2026-05-14T11:05:00.000Z*
### [Larimar Therapeutics (LRMR) Expected to Announce Earnings on Monday](https://longbridge.com/en/news/280101340.md)
*2026-03-23T05:10:35.000Z*
> Larimar Therapeutics (NASDAQ:LRMR) is set to announce its Q4 2025 earnings on March 30, with analysts predicting a loss 

### [Larimar Therapeutics (NASDAQ:LRMR) Stock Price Up 8.2% After Analyst Upgrade](https://longbridge.com/en/news/279975793.md)
*2026-03-20T17:07:44.000Z*
> Larimar Therapeutics (NASDAQ:LRMR) shares rose 8.2% after Wedbush upgraded its price target from $12.00 to $13.00, maint

### [Larimar Therapeutics | 10-K: FY2025 Revenue: USD 0](https://longbridge.com/en/news/279839994.md)
*2026-03-19T19:44:16.000Z*